Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery.
about
Use of lectin-functionalized particles for oral immunotherapyNanoformulated cell-penetrating survivin mutant and its dual actions.Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength.CD137 is required for M cell functional maturation but not lineage commitmentM cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responsesIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Intranasal inoculation of white-tailed deer (Odocoileus virginianus) with lyophilized chronic wasting disease prion particulate complexed to montmorillonite clayPreparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticlesEnteroendocrine cells are specifically marked by cell surface expression of claudin-4 in mouse small intestine.M cell-derived vesicles suggest a unique pathway for trans-epithelial antigen delivery.Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse modelC-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal VaccineSoluble RANKL expression in Lactococcus lactis and investigation of its potential as an oral vaccine adjuvant.Tight junction CLDN2 gene is a direct target of the vitamin D receptor.Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium.Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugatesEpithelial barrier and antigen uptake in lymphoepithelium of human adenoids.Regulation of tight junctions in upper airway epithelium.Basics and recent advances in peptide and protein drug delivery.Orally active-targeted drug delivery systems for proteins and peptides.PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Drug Release and Targeting: the Versatility of Polymethacrylate Nanoparticles for Peroral Administration Revealed by Using an Optimized In Vitro-Toolbox.Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.Intranasal delivery of nanoparticle-based vaccines.Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration.Mucosal vaccine delivery: is M cell-targeted delivery effective in the mucosal lumen?Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay.Self-discriminating fluorescent hybrid nanocrystals: efficient and accurate tracking of translocation via oral delivery.Impaired airway mucociliary function reduces antigen-specific IgA immune response to immunization with a claudin-4-targeting nasal vaccine in mice.Inflammation and intestinal leakiness in older HIV+ individuals with fish oil treatmentDevelopment of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity of Enterotoxin
P2860
Q26849550-DFFB0083-2018-4DBA-953B-8C848FCACF3AQ33904982-96D890B6-C61A-44B7-A735-21126E29B47BQ34025399-0558934E-05C0-484E-91B5-7F51430E78C4Q34033430-FD281F87-E94F-4939-A039-146B78258DF4Q34194207-2E46F2CE-171F-4641-B7C4-36D1AFC0CD88Q34309830-18EC1617-E07B-4EBC-9C6C-6B54B654C930Q34720600-0D6A80D1-2843-4991-8EC2-FCE681A8EBE5Q35080032-A86A78AA-83A0-4CFF-93BB-77919C6660A6Q35112967-46463FE4-A954-47A9-9682-E7D529AFF19FQ35212847-C6386E61-73AF-4999-AA62-27FF5E6F9397Q35588631-2A00F638-5D8F-45DF-BA52-31F96C806A99Q35643907-834AB997-1329-4FE7-8578-BE85F892BCE9Q35853148-EC1EE5E8-4D4A-404A-8CE1-B998F0FFAECDQ36293734-44E2D0A1-8104-49A3-9B06-49806E641248Q36940409-37499C6B-5FB2-4A85-837E-CE952A6E0F36Q37238542-86C9FE78-0930-4AF8-8939-8016211E54B1Q37808213-7C1C3760-5436-465A-B4F7-8E3C985DCFFEQ38091094-DF8AFD9F-FE7C-438C-89A6-D452175BFAD4Q38162494-3D103CB5-273E-41C3-A162-ED4E5CDD3429Q38223053-BA4CA621-43D9-41F9-8588-A6C6B69A76C8Q38692217-1635CCCB-4A74-4DE2-8ED7-DC6E533DA135Q38848809-F70299FE-9E09-4278-9EF8-61DA85CCA101Q38862706-F09C4606-E5F2-41A4-9F55-294483F1B90CQ39113247-452D9F7E-37AC-483A-B9D1-8FDEFAD0FFA9Q39390000-6F662F50-18DE-4622-A7AD-A0AAF216D7DBQ41244310-9D8267B8-2893-44D0-A1D6-4783A34441AEQ44681342-ED1B7EAB-E7E7-4352-AE67-0F839BF88B56Q47104566-26A26BC5-0802-4ECB-B06A-4ED302EE42B9Q47760779-7D2C982E-D6B0-4A48-B010-C411B2A5C585Q50025743-669492DE-E39E-49B8-B1D9-2454B419E2A4Q57496206-5561DB6D-541A-4CFA-8142-B6EE33F0601CQ57816705-C8159F20-249A-4888-92DF-012AD5ECC032
P2860
Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@ast
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@en
type
label
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@ast
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@en
prefLabel
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@ast
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@en
P2093
P2860
P1476
Claudin 4-targeted protein inc ...... iate M cell targeted delivery.
@en
P2093
David D Lo
Holly A Eckelhoefer
Mary Stover-Hamer
Thejani E Rajapaksa
Xiomara Fernandez
P2860
P304
P356
10.1016/J.JCONREL.2009.10.033
P407
P577
2009-11-05T00:00:00Z